company background image
ALPM.F logo

Astellas Pharma OTCPK:ALPM.F Stock Report

Last Price

US$10.27

Market Cap

US$17.7b

7D

-2.2%

1Y

-13.0%

Updated

22 Dec, 2024

Data

Company Financials +

Astellas Pharma Inc.

OTCPK:ALPM.F Stock Report

Market Cap: US$17.7b

My Notes

Capture your thoughts, links and company narrative

Astellas Pharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Astellas Pharma
Historical stock prices
Current Share PriceJP¥10.27
52 Week HighJP¥12.74
52 Week LowJP¥9.13
Beta0.23
1 Month Change6.08%
3 Month Changen/a
1 Year Change-12.97%
3 Year Change-35.81%
5 Year Change-40.08%
Change since IPO-64.74%

Recent News & Updates

Recent updates

Shareholder Returns

ALPM.FUS PharmaceuticalsUS Market
7D-2.2%-1.5%-2.4%
1Y-13.0%7.9%23.4%

Return vs Industry: ALPM.F underperformed the US Pharmaceuticals industry which returned 7.8% over the past year.

Return vs Market: ALPM.F underperformed the US Market which returned 23.3% over the past year.

Price Volatility

Is ALPM.F's price volatile compared to industry and market?
ALPM.F volatility
ALPM.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ALPM.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ALPM.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
192314,754Naoki Okamurawww.astellas.com

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.

Astellas Pharma Inc. Fundamentals Summary

How do Astellas Pharma's earnings and revenue compare to its market cap?
ALPM.F fundamental statistics
Market capUS$17.66b
Earnings (TTM)US$350.13m
Revenue (TTM)US$11.33b

50.4x

P/E Ratio

1.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALPM.F income statement (TTM)
RevenueJP¥1.77t
Cost of RevenueJP¥322.95b
Gross ProfitJP¥1.45t
Other ExpensesJP¥1.39t
EarningsJP¥54.75b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)30.58
Gross Margin81.78%
Net Profit Margin3.09%
Debt/Equity Ratio61.2%

How did ALPM.F perform over the long term?

See historical performance and comparison

Dividends

4.8%

Current Dividend Yield

350%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:02
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Astellas Pharma Inc. is covered by 31 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hazim BahariCFRA Equity Research